B细胞在自身免疫病治疗中的地位决定疗效：一项系统性综述
B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review
B细胞通过产生自身抗体、呈递抗原和分泌细胞因子等方式参与自身免疫病，但不同疾病对靶向B细胞治疗的反应差别很大。本综述系统检索2020年至2025年7月的临床试验，纳入5种自身免疫病（天疱疮、重症肌无力、类风湿关节炎、系统性硬化症、干燥综合征）共24项试验、3500余名受试者。结果显示：以自身抗体为主要致病机制的疾病（如天疱疮、重症肌无力）对B细胞清除治疗反应最好且持久；免疫复合物相关疾病（如类风湿关节炎）疗效有限；BTK抑制剂起效快但不持久；靶向BCMA的CAR-T细胞疗法在重症肌无力中显示出持久缓解的潜力。作者认为，疗效好坏与疾病中B细胞的参与程度和清除深度有关，需要精准选择患者。
为什么推荐给您：系统汇总多种B细胞靶向策略的疗效差异，提出按疾病机制精准选择，属重要综述性整合。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
BACKGROUND: B cells play a critical role in autoimmunity through autoantibody production, plasma cell differentiation, antigen presentation, cytokine secretion, and germinal center responses. The clinical efficacy, durability, and safety profiles vary across autoimmune diseases. Therefore, the objective is to assess B-cell therapeutic responses and their correlation with disease pathology in autoimmunity.
METHODS: Embase, Web of Science, and PubMed were systematically screened for clinical trials published between 2020 and July 2025. A total of 24 clinical trials across five autoimmune conditions-pemphigus vulgaris, myasthenia gravis, rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome-were evaluated for B-cell-targeted therapy. Interventions included B-cell depletion therapy, CAR-T cell therapy, BTK inhibition, rituximab and its biosimilars, and combination strategies.
RESULTS: Across 24 clinical trials, more than 3,500 participants were included. We observed that autoantibody-mediated diseases pemphigus vulgaris and myasthenia gravis had the most superior and durable immune response to B-cell depletion by rituximab and inebilizumab, respectively. BTK inhibition showed rapid but non-durable responses. Immune complex diseases like rheumatoid arthritis and systemic sclerosis showed improvement in activity scores and partial response, and no clinical remission after treatment with rituximab and its biosimilars. The next-generation approach BCMA-directed CAR T-cell therapy showed promising results with potential durability in myasthenia gravis. Combination therapy using belimumab and rituximab resulted in a significantly better clinical outcome than monotherapy in Sjögren's syndrome. Overall, B-cell therapy safety profiles showed no severe adversity and were well tolerated.
CONCLUSIONS: The success of B-cell therapeutics appears to align with B-cell contribution, disease biology, and the depth of B-cell targeting in autoimmune conditions. Precision targeting is needed to effectively combat autoimmune diseases.